Given the recent advances in treating mutant RET+ cancer, I want to take this opportunity to highlight our publication in @Leukemia (2018) entitled “RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia”.
🧵 (1/13)

rdcu.be/b6yGD The #RET gene encodes a receptor tyrosine kinase (RTK), whose activating mutations are prevalent in solid-organ malignancies such as thyroid cancer (TC) or non-small cell lung cancer (#NSCLC). In contrast, the role of RET in haematologic malignancies is less well defined. (2/13)